Suppr超能文献

评估肥胖患者的非酒精性脂肪性肝病和纤维化:组织学和临床评分系统的比较。

Evaluation of NAFLD and fibrosis in obese patients - a comparison of histological and clinical scoring systems.

机构信息

Department of General, Visceral and Transplantation Surgery, RWTH Aachen University Hospital, Pauwelsstr.30, 52074, Aachen, Germany.

Department of Surgery, Maastricht University Medical Center, P. Debyelaan 25, 6229, Maastricht, HX, Netherlands.

出版信息

BMC Gastroenterol. 2020 Aug 5;20(1):254. doi: 10.1186/s12876-020-01400-1.

Abstract

BACKGROUND

Non-alcoholic fatty liver disease (NAFLD) is a frequent condition in obese patients and regularly progresses to non-alcoholic steatohepatitis (NASH) and subsequent cirrhosis. Histologic evaluation is the gold standard for grading and staging, but invasive biopsies are associated with obvious risks. The aim of this study was to evaluate different non-invasive tools for screening of NAFLD and fibrosis in obese patients.

METHODS

In a prospective cohort study liver specimens of 141 patients were taken during bariatric surgery. Serological parameters and clinical data were collected and the following scores calculated: NASH clinical scoring system (NCS), aspartate aminotransferase to platelet ratio index (APRI), FIB-4 as well as NAFLD fibrosis score (NFS). Liver function capacity was measured preoperatively by LiMAx test (enzymatic capacity of cytochrome P450 1A2). Intraoperative liver biopsies were classified using NAFLD activity score (NAS) and steatosis, activity and fibrosis (SAF) score.

RESULTS

APRI was able to differentiate between not NASH and definite NASH with a sensitivity of 74% and specificity of 67% (AUROC 0.76). LiMAx and NCS also showed significant differences between not NASH and definite NASH. No significant differences were found for NFS and Fib-4. APRI had a high sensitivity (83%) and specificity (76%) in distinguishing fibrosis from no fibrosis (AUROC = 0.81). NCS and Fib-4 also revealed high AUROCs (0.85 and 0.67), whereas LiMAx and NFS did not show statistically significant differences between fibrosis stages. Out of the patients with borderline NASH in the histologic NAS score, 48% were classified as NASH by SAF score.

CONCLUSIONS

APRI allows screening of NAFLD as well as fibrosis in obese patients. This score is easy to calculate and affordable, while conveniently only using routine clinical parameters. Using the NAS histologic scoring system bears the risk of underdiagnosing NASH in comparison to SAF score.

摘要

背景

非酒精性脂肪性肝病(NAFLD)是肥胖患者的常见病症,常进展为非酒精性脂肪性肝炎(NASH)和随后的肝硬化。组织学评估是分级和分期的金标准,但侵入性活检存在明显风险。本研究旨在评估不同的非侵入性工具在肥胖患者中筛查 NAFLD 和纤维化的效果。

方法

在一项前瞻性队列研究中,在减肥手术期间对 141 名患者的肝组织进行了取样。收集了血清学参数和临床数据,并计算了以下评分:NASH 临床评分系统(NCS)、天门冬氨酸氨基转移酶与血小板比值指数(APRI)、FIB-4 以及 NAFLD 纤维化评分(NFS)。术前通过 LiMAx 试验(细胞色素 P450 1A2 的酶活性)测量肝功能。术中肝活检采用 NAFLD 活动评分(NAS)和脂肪变性、活动和纤维化(SAF)评分进行分类。

结果

APRI 能够区分无 NASH 和明确的 NASH,其敏感性为 74%,特异性为 67%(AUROC 为 0.76)。LiMAx 和 NCS 也在无 NASH 和明确的 NASH 之间显示出显著差异。NFS 和 Fib-4 之间没有发现显著差异。APRI 在区分纤维化与非纤维化方面具有较高的敏感性(83%)和特异性(76%)(AUROC=0.81)。NCS 和 Fib-4 也显示出较高的 AUROC(0.85 和 0.67),而 LiMAx 和 NFS 之间在纤维化分期方面没有统计学上的显著差异。在组织学 NAS 评分中处于边缘性 NASH 的患者中,48%根据 SAF 评分被归类为 NASH。

结论

APRI 可用于筛查肥胖患者的 NAFLD 及纤维化。该评分易于计算且经济实惠,仅使用常规临床参数即可。与 SAF 评分相比,使用 NAS 组织学评分系统存在低估 NASH 的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b78/7405451/94698d3cc801/12876_2020_1400_Fig4_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验